Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review
TLDR
Improving adherence in schizophrenia may have a considerable positive impact on patients and society by focusing on the identified multitude of factors driving nonadherence, including lack of insight, medication beliefs and substance abuse.Abstract:
Background:Nonadherence to medication is a recognized problem and may be the most challenging aspect of treatment.Methods:We performed a systematic review of factors that influence adherence and the consequences of nonadherence to the patient, healthcare system and society, in patients with schizophrenia. Particular attention was given to the effect of nonadherence on hospitalization rates, as a key driver of increased costs of care. A qualitative systematic literature review was conducted using a broad search strategy using disease and adherence terms. Due to the large number of abstracts identified, article selection was based on studies with larger sample sizes published after 2001. Thirty-seven full papers were included: 15 studies on drivers and 22 on consequences, of which 12 assessed the link between nonadherence and hospitalization.Results:Key drivers of nonadherence included lack of insight, medication beliefs and substance abuse. Key consequences of nonadherence included greater risk of relapse,...read more
Citations
More filters
Journal ArticleDOI
Medication nonadherence in bipolar disorder: a narrative review.
TL;DR: Clinicians should routinely enquire about nonadherence in a nonjudgmental fashion and potential steps to improve adherence include simple pragmatic strategies related to prescribing including shared decision-making, psychoeducation with a clear focus on adherence and managing comorbid substance misuse and improving therapeutic alliance.
Journal ArticleDOI
Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia: Findings From a 12-Week, Randomized, Double-Blind, Placebo-Controlled Study
John M. Kane,Timothy Peters-Strickland,Ross A. Baker,Peter Hertel,Anna Eramo,Na Jin,Pamela Perry,Michelle Gara,Robert D. McQuade,William H. Carson,Raymond Sanchez +10 more
TL;DR: Symptoms and functioning improved with AOM 400 mg versus placebo in patients with acute schizophrenia, with acceptable safety and tolerability, suggest that A OM 400 mg is a viable treatment option for patients experiencing an acute schizophrenia episode.
Journal ArticleDOI
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Dominic Pilon,Neeta Tandon,Marie-Hélène Lafeuille,Rhiannon Kamstra,Bruno Emond,Patrick Lefebvre,Kruti Joshi +6 more
TL;DR: Second-generation long-acting injectable therapies (SGA-LAIs) may reduce health care resource utilization (HRU) and health care costs compared with daily oral atypical antipsychotics (OAAs) in patients with schizophrenia due to reduced dosing frequency, delivery/monitoring by a health care provider, and improved adherence.
Journal ArticleDOI
Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics.
TL;DR: Key elements to take into account when offering a LAI in the early course of schizophrenia should include their potential superiority in allowing early detection of non-adherence and in reducing the number of rehospitalisations and relapses.
Journal ArticleDOI
Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study
TL;DR: A path analysis revealed a positive impact of insight on adherence and alliance and that stronger alliance was related to lower clinical severity (lower CGI score).
References
More filters
Journal ArticleDOI
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati,Douglas G. Altman,Jennifer Tetzlaff,Cynthia D. Mulrow,Peter C Gøtzsche,John P. A. Ioannidis,Mike Clarke,Mike Clarke,Philip J. Devereaux,Jos Kleijnen,David Moher +10 more
TL;DR: An Explanation and Elaboration of the PRISMA Statement is presented and updated guidelines for the reporting of systematic reviews and meta-analyses are presented.
Journal ArticleDOI
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati,Douglas G. Altman,Jennifer Tetzlaff,Cynthia D. Mulrow,Peter C Gøtzsche,John P. A. Ioannidis,Mike Clarke,Mike Clarke,Philip J. Devereaux,Jos Kleijnen,David Moher +10 more
TL;DR: This Explanation and Elaboration document explains the meaning and rationale for each checklist item and includes an example of good reporting and, where possible, references to relevant empirical studies and methodological literature.
Journal ArticleDOI
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman,T. Scott Stroup,Joseph P. McEvoy,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Richard S.E. Keefe,Sonia M. Davis,C.E. Davis,Barry D. Lebowitz,Joanne B. Severe,John K. Hsiao +12 more
TL;DR: Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Journal ArticleDOI
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
Alan S. Bellack,Charles L. Bowden,Christopher R. Bowie,Matthew J. Byerly,William T. Carpenter,Laurel A. Copeland,Albana M Dassori,John M. Davis,Colin A. Depp,Esperanza Diaz,Lisa B. Dixon,John P. Docherty,Eric B. Elbogen,S. Nasser Ghaemi,Paul E. Keck,Samuel J. Keith,Martijn J. Kikkert,John Lauriello,Barry D. Lebotz,Stephen R. Marder,Joseph P. McEvoy,David J. Miklowitz,Alexander L. Miller,Paul A. Nakonezny,Henry A. Nasrallah,Michael W. Otto,Roy H. Perlis,Delbert G. Robinson,Gary S. Sachs,Martha Sajatovic,Nina R. Schooler,S. Charles Schulz,Jan Scoff,Jair C. Soares,Stephen M. Strakowski,Holly A. Swartz,Marcia Valenstein,Dawn I. Velligan,Peter J. Weiden,Emily M. Woltmann,John E. Zeber +40 more
TL;DR: Recommendations for addressing adherence problems to improve patient outcomes are developed, noting that multiple problems may be involved, requiring a combination of interventions.
Journal ArticleDOI
Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia
TL;DR: This study showed a direct correlation between estimated partial compliance and hospitalization risk among patients with schizophrenia across a continuum of compliance behavior.
Related Papers (5)
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
Alan S. Bellack,Charles L. Bowden,Christopher R. Bowie,Matthew J. Byerly,William T. Carpenter,Laurel A. Copeland,Albana M Dassori,John M. Davis,Colin A. Depp,Esperanza Diaz,Lisa B. Dixon,John P. Docherty,Eric B. Elbogen,S. Nasser Ghaemi,Paul E. Keck,Samuel J. Keith,Martijn J. Kikkert,John Lauriello,Barry D. Lebotz,Stephen R. Marder,Joseph P. McEvoy,David J. Miklowitz,Alexander L. Miller,Paul A. Nakonezny,Henry A. Nasrallah,Michael W. Otto,Roy H. Perlis,Delbert G. Robinson,Gary S. Sachs,Martha Sajatovic,Nina R. Schooler,S. Charles Schulz,Jan Scoff,Jair C. Soares,Stephen M. Strakowski,Holly A. Swartz,Marcia Valenstein,Dawn I. Velligan,Peter J. Weiden,Emily M. Woltmann,John E. Zeber +40 more